MCID: INV006
MIFTS: 41

Inverted Papilloma malady

Categories: Cancer diseases

Aliases & Classifications for Inverted Papilloma

Aliases & Descriptions for Inverted Papilloma:

Name: Inverted Papilloma 12 14 69
Inverted Papilloma, Squamous Cell 12
Inverted Squamous Cell Papilloma 69
Papilloma, Inverted 42
Papilloma Inverted 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3179
MeSH 42 D018308
NCIt 47 C3793
SNOMED-CT 64 104081000119103
UMLS 69 C0206721

Summaries for Inverted Papilloma

MalaCards based summary : Inverted Papilloma, also known as inverted papilloma, squamous cell, is related to frontal sinus inverted papilloma and maxillary sinus inverted papilloma. An important gene associated with Inverted Papilloma is KRT13 (Keratin 13), and among its related pathways/superpathways are Cell cycle and DNA Damage. The drugs Fentanyl and Cevimeline have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and t cells.

Wikipedia : 71 An inverted papilloma is a type of tumor in which surface epithelial cells grow downward into the... more...

Related Diseases for Inverted Papilloma

Diseases related to Inverted Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
id Related Disease Score Top Affiliating Genes
1 frontal sinus inverted papilloma 12.2
2 maxillary sinus inverted papilloma 12.2
3 sphenoid sinus inverted papilloma 12.2
4 ureter inverted papilloma 12.0
5 renal pelvis inverted papilloma 12.0
6 ethmoid sinus inverted papilloma 12.0
7 urethra inverted papilloma 12.0
8 nasal cavity inverting papilloma 12.0
9 urinary bladder inverted papilloma 12.0
10 inverted transitional papilloma 11.1
11 urinary tract papillary transitional cell benign neoplasm 11.1
12 papilloma 11.1
13 sinusitis 10.5
14 squamous cell carcinoma 10.5
15 wolffian adnexal neoplasm 10.3 MKI67 TP53
16 clear cell adenofibroma 10.3 CDKN2A TP53
17 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
18 aml with myelodysplasia-related features 10.3 CDKN2A MKI67
19 bladder adenocarcinoma 10.3 CDKN2A MKI67
20 lacrimal gland squamous cell carcinoma 10.3 CDKN2A TP53
21 lymphangitis 10.3 KRT13 TP53
22 endometrial squamous cell carcinoma 10.3 CDKN2A TP53
23 ampulla of vater neoplasm 10.3 CDKN2A TP53
24 maxillary sinus schneiderian papilloma 10.3 KRT13 KRT5
25 coccidiosis 10.3 CDKN2A TP53
26 extrahepatic cholestasis 10.3 KRT13 KRT5
27 postpoliomyelitis syndrome 10.3 CDKN2A TP53
28 anal carcinoma in situ 10.3 CDKN2A TP53
29 sclerosing breast papilloma 10.3 KRT5 TP53
30 brain stem medulloblastoma 10.2 CDKN2A TP53
31 choriocarcinoma of ovary 10.2 KRT5 TP53
32 uterine disease 10.2 CDKN2A TP53
33 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
34 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
35 suppurative lymphadenitis 10.2 CDKN2A KRT5
36 adult epithelioid sarcoma 10.2 CDKN2A TP53
37 cervical verrucous carcinoma 10.2 CDKN2A TP53
38 transitional cell carcinoma 10.2
39 uterine cervix leukoplakia 10.2 CDKN2A TP53
40 spastic paraplegia 1 10.2 MKI67 TP53
41 diffuse pulmonary fibrosis 10.2 CDKN2A KRT5
42 house allergic alveolitis 10.2 CDKN2A TP53
43 brachydactyly small stature face anomalies 10.2 MKI67 PCNA
44 acquired hemangioma 10.2 CDKN2A TP53
45 urethral verrucous carcinoma 10.2 CDKN2A TP53
46 spinal cord intramedullary teratoma 10.2 KRT5 TP53
47 inhibited male orgasm 10.2 PCNA TP53
48 pyloric antrum cancer 10.2 PCNA TP53
49 spondylarthropathy 10.2 CDKN2A MKI67 TP53
50 common bile duct neoplasm 10.2 MKI67 PCNA

Graphical network of the top 20 diseases related to Inverted Papilloma:



Diseases related to Inverted Papilloma

Symptoms & Phenotypes for Inverted Papilloma

Drugs & Therapeutics for Inverted Papilloma

Drugs for Inverted Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
3
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
5
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
9 Liver Extracts Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents Phase 2, Phase 3,Phase 1
11 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
12 Adjuvants, Anesthesia Phase 3
13 Analgesics Phase 3
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Central Nervous System Depressants Phase 3
19 Narcotics Phase 3
20 pancreatic polypeptide Phase 3
21 Peripheral Nervous System Agents Phase 3
22 Autonomic Agents Phase 3
23 Cholinergic Agents Phase 3
24 Neurotransmitter Agents Phase 3
25 Antifungal Agents Phase 2, Phase 3,Phase 1
26 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3
28 Hormones Phase 2, Phase 3,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
30 Steroid Synthesis Inhibitors Phase 2, Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Appetite Stimulants Phase 3
33 Central Nervous System Stimulants Phase 3
34 Contraceptive Agents Phase 3
35 Contraceptives, Oral Phase 3
36
Megestrol Phase 3 3562-63-8 19090 3080587
37 Antimitotic Agents Phase 3,Phase 2,Phase 1
38 Antidepressive Agents Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Histamine Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Psychotropic Drugs Phase 3
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
47
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
48
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
49
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
50
Etoposide Approved Phase 2 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 60)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
4 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
8 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
9 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
10 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
11 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
14 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
15 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2
16 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2
17 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
18 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2
19 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
20 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
21 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
22 Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer Unknown status NCT00896350 Phase 1
23 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1
24 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1
25 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
26 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
27 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
28 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
29 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1
30 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1
31 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
32 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
33 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
34 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1
35 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1
36 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
37 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1
38 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
39 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
40 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
41 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1
42 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1
43 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1
44 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1
45 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
46 Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava Completed NCT01827423
47 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497
48 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947
49 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
50 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793

Search NIH Clinical Center for Inverted Papilloma

Cochrane evidence based reviews: papilloma, inverted

Genetic Tests for Inverted Papilloma

Anatomical Context for Inverted Papilloma

MalaCards organs/tissues related to Inverted Papilloma:

39
Bone, Prostate, T Cells, Cervix, Endothelial, Skin, Pituitary

Publications for Inverted Papilloma

Articles related to Inverted Papilloma:

(show top 50) (show all 554)
id Title Authors Year
1
Ossifying inverted papilloma and ossifying polypA of the sinonasal tract: comparison ofA CTA andA MRI features. ( 27773333 )
2017
2
Sinonasal inverted papilloma: From diagnosis to treatment. ( 27053431 )
2016
3
Re-affirming the necessity of sending even minor surgical specimens for histopathology: a case of inverted papilloma of the adenoids. ( 27685930 )
2016
4
Inverted Papilloma of the Bladder Coexisting with Urothelial Carcinoma. A Case Report. ( 27363067 )
2016
5
Smoking, not human papilloma virus infection, is a risk factor for recurrence of sinonasal inverted papilloma. ( 26980388 )
2016
6
Primary Inverted Papilloma of Middle Ear and Mastoid: A Rare Case Report. ( 27190934 )
2016
7
Intestinal Type Adenocarcinoma from Inverted Papilloma: A Rare Recurrence. ( 28050382 )
2016
8
Survival outcomes after endoscopic resection for sinonasal squamous cell carcinoma arising on inverted papilloma. ( 27152722 )
2016
9
Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma. ( 26877539 )
2016
10
Management Strategies for Skull Base Inverted Papilloma. ( 27026729 )
2016
11
Primary inverted papilloma of the middle ear with intracranial invasion. ( 26698908 )
2016
12
Recurrence of sinonasal inverted papilloma following surgical approach: A meta-analysis. ( 27531693 )
2016
13
Rhinogenic intracranial complication with postoperative frontal sinus pyocele and inverted papilloma in the nasal cavity: A case report and literature review. ( 27489711 )
2016
14
Bilateral multifocal inverted papilloma with osseous metaplasia of the sinonasal cavity. ( 27542897 )
2016
15
Prediction of the originating site of sinonasal inverted papilloma by preoperative magnetic resonance imaging and computed tomography. ( 27557563 )
2016
16
Atypical presentations of sinonasal inverted papilloma: Surgical management and influence on the recurrence rate. ( 26980397 )
2016
17
The prevalence of human papillomavirus infection in Iranian patients with sinonasal inverted papilloma. ( 26782082 )
2016
18
Removal of inverted papilloma from the frontal recess: how we do it. ( 26860209 )
2016
19
Basaloid squamous cell carcinoma arising in an inverted papilloma in the nasal cavity: A case report and review. ( 27720480 )
2016
20
Postoperative value of serum squamous cell carcinoma antigen as a predictor of recurrence in sinonasal inverted papilloma. ( 27717197 )
2016
21
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma. ( 27108101 )
2016
22
Rate of recurrence and malignant transformation in 88 cases with inverted papilloma between 1998-2008. ( 26838581 )
2016
23
Mucocele formation after surgical treatment of inverted papilloma of the frontal sinus drainage pathway. ( 27657893 )
2016
24
Squamous cell carcinoma associated with inverted papilloma of the maxillary sinus: our experience with 21 patients. ( 27930867 )
2016
25
Inverted papilloma: The stubbornly persistent tumor of the sinonasal cavity. ( 26980387 )
2016
26
Human papillomavirus infection and the malignant transformation of sinonasal inverted papilloma: A meta-analysis. ( 27085508 )
2016
27
Is radical surgery of an inverted papilloma of the maxillary sinus obsolete? a case report. ( 27906054 )
2016
28
Challenges in the Management of Inverted Papilloma: A Review of 72 Revision Cases. ( 26344930 )
2015
29
Inverted Papilloma Originating Primarily from the Nasolacrimal Duct: A Case Report and Review of the Pertinent Literature. ( 26649215 )
2015
30
Positron emission tomography evaluation of sinonasal inverted papilloma and related conditions: a prospective clinical study. ( 25934400 )
2015
31
Management and treatment of sinonasal inverted papilloma. ( 26941894 )
2015
32
Inverted papilloma of the maxillary sinus: Surgical approach and long-term results. ( 26637584 )
2015
33
Role of Wnt signaling pathway in progression of sinonasal inverted papilloma to squamous cell carcinoma. ( 25975243 )
2015
34
Inverted papilloma originating from the left ethmoid sinus invading the nasal cavity bilaterally via the frontal sinus septum. ( 26480905 )
2015
35
Imaging Features of Sinonasal Inverted Papilloma: A Pictorial Review. ( 26632214 )
2015
36
Aggressive human papillomavirus (HPV)-11-related sinonasal inverted papilloma in an HIV-infected patient and the quadrivalent HPV vaccine: a case report. ( 26544709 )
2015
37
Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma. ( 26020249 )
2015
38
Rhinosinusal Polyposis and Inverted Papilloma: A Morphometric Comparative Study. ( 26157491 )
2015
39
Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. ( 26679899 )
2015
40
Sinonasal inverted papilloma: A case report and mini review of histopathological features. ( 26980974 )
2015
41
Surgical risk factors for recurrence of inverted papilloma. ( 26372045 )
2015
42
Inverted papilloma of lacrimal sac invading into the orbit: Case report and review of literature. ( 25879369 )
2015
43
Inverted papilloma of frontal sinus with intracranial extension. ( 26265814 )
2015
44
High-resolution microendoscope imaging of inverted papilloma and normal sinonasal mucosa: evaluation of interobserver concordance. ( 26228817 )
2015
45
Metallothionein 2A core promoter region genetic polymorphism and its impact on the risk, tumor behavior, and recurrences of sinonasal inverted papilloma (Schneiderian papilloma). ( 26036762 )
2015
46
Endoscopic Modified Medial Maxillectomy for Resection of an Inverted Papilloma Originating from the Entire Circumference of the Maxillary Sinus. ( 26146581 )
2015
47
Endoscopic modified medial maxillectomy for treatment of inverted papilloma originating from the maxillary sinus. ( 25915667 )
2015
48
A clinical and molecular review of inverted papilloma of the urinary tract: how to handle? ( 26358542 )
2015
49
The effect of metallothionein 2A core promoter region single-nucleotide polymorphism on accumulation of toxic metals in sinonasal inverted papilloma tissues. ( 25900616 )
2015
50
Inverted papilloma of the sphenoid sinus: risk factors for disease recurrence. ( 25418985 )
2015

Variations for Inverted Papilloma

Cosmic variations for Inverted Papilloma:

9 (show all 17)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM496 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 16
2 COSM29437 FGFR3 urinary tract,bladder,papilloma,inverted c.1881G>T p.E627D 16
3 COSM29432 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259L 16
4 COSM29438 FGFR3 urinary tract,bladder,papilloma,inverted c.1921G>A p.D641N 16
5 COSM29431 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 16
6 COSM29436 FGFR3 urinary tract,bladder,papilloma,inverted c.1236C>T p.H412H 16
7 COSM29434 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 16
8 COSM29440 FGFR3 urinary tract,bladder,papilloma,inverted c.1957A>C p.N653H 16
9 COSM29439 FGFR3 urinary tract,bladder,papilloma,inverted c.1927C>G p.H643D 16
10 COSM10742 TP53 urinary tract,bladder,papilloma,NS c.578A>G p.H193R 9
11 COSM43749 TP53 urinary tract,bladder,papilloma,NS c.595G>A p.G199R 9
12 COSM44602 TP53 urinary tract,bladder,papilloma,NS c.562C>G p.L188V 9
13 COSM43814 TP53 urinary tract,bladder,papilloma,NS c.587G>C p.R196P 9
14 COSM10801 TP53 urinary tract,bladder,papilloma,NS c.404G>A p.C135Y 9
15 COSM715 FGFR3 urinary tract,bladder,papilloma,NS c.746C>G p.S249C 9
16 COSM718 FGFR3 urinary tract,bladder,papilloma,NS c.1118A>G p.Y373C 9
17 COSM714 FGFR3 urinary tract,bladder,papilloma,NS c.742C>T p.R248C 9

Expression for Inverted Papilloma

Search GEO for disease gene expression data for Inverted Papilloma.

Pathways for Inverted Papilloma

Pathways related to Inverted Papilloma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.01 CDKN2A PCNA TP53
2 11.72 CDKN2A MKI67 PCNA TP53
3 11.56 CDKN2A PCNA TP53
4 11.36 CDKN2A PCNA TP53
5 11.33 CDKN2A MSX2 PCNA TP53
6 10.96 PCNA TP53
7 10.94 CDKN2A TP53
8 10.87 PCNA TP53
9 10.71 CDKN2A TP53
10
Show member pathways
10.66 CDKN2A TP53

GO Terms for Inverted Papilloma

Cellular components related to Inverted Papilloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.13 KRT13 KRT20 KRT5
2 replication fork GO:0005657 8.62 PCNA TP53

Biological processes related to Inverted Papilloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.33 KRT13 KRT20 KRT5
2 cornification GO:0070268 9.13 KRT13 KRT20 KRT5
3 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Inverted Papilloma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 histone acetyltransferase binding GO:0035035 8.62 PCNA TP53

Sources for Inverted Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....